Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBIO NASDAQ:BEAM NASDAQ:DNLI NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBIOBridgeBio Pharma$47.02+0.6%$39.54$21.72▼$48.68$8.91B1.152.54 million shs526,558 shsBEAMBeam Therapeutics$21.17+3.5%$17.97$13.53▼$35.25$2.13B2.071.57 million shs778,958 shsDNLIDenali Therapeutics$14.46-0.5%$14.24$10.57▼$33.33$2.10B1.331.14 million shs79,460 shsVRNAVerona Pharma PLC American Depositary Share$104.89+0.1%$86.72$18.51▼$104.99$8.93B0.242.30 million shs1.09 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBIOBridgeBio Pharma-0.76%+1.02%+16.65%+38.00%+66.99%BEAMBeam Therapeutics+1.89%-7.17%+22.68%+20.29%-24.06%DNLIDenali Therapeutics-2.29%-5.34%+3.71%+14.05%-36.85%VRNAVerona Pharma PLC American Depositary Share+0.04%-0.07%+12.75%+77.83%+358.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBIOBridgeBio Pharma4.6339 of 5 stars4.51.00.03.93.13.30.6BEAMBeam Therapeutics2.0801 of 5 stars3.50.00.00.02.52.50.6DNLIDenali Therapeutics4.6241 of 5 stars4.51.00.04.73.43.30.0VRNAVerona Pharma PLC American Depositary Share2.3122 of 5 stars2.15.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBIOBridgeBio Pharma 3.00Buy$61.2030.94% UpsideBEAMBeam Therapeutics 3.00Buy$48.75138.39% UpsideDNLIDenali Therapeutics 3.06Buy$33.71132.03% UpsideVRNAVerona Pharma PLC American Depositary Share 2.15Hold$109.004.03% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, BEAM, BBIO, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025BBIOBridgeBio PharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $68.007/14/2025BBIOBridgeBio PharmaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.007/14/2025VRNAVerona Pharma PLC American Depositary ShareHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$90.00 ➝ $107.007/11/2025BBIOBridgeBio PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $67.007/10/2025VRNAVerona Pharma PLC American Depositary SharePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/10/2025VRNAVerona Pharma PLC American Depositary ShareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$138.00 ➝ $107.007/10/2025VRNAVerona Pharma PLC American Depositary ShareBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/9/2025VRNAVerona Pharma PLC American Depositary ShareCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold7/9/2025BBIOBridgeBio PharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$60.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBIOBridgeBio Pharma$221.90M40.00N/AN/A($7.71) per share-6.06BEAMBeam Therapeutics$63.52M32.37N/AN/A$8.86 per share2.31DNLIDenali Therapeutics$330.53M6.39N/AN/A$8.53 per share1.70VRNAVerona Pharma PLC American Depositary Share$42.28M210.97N/AN/A$2.56 per share40.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBIOBridgeBio Pharma-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)BEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)DNLIDenali Therapeutics-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)VRNAVerona Pharma PLC American Depositary Share-$173.42M-$2.00N/A3,492.67N/AN/A-69.65%-28.00%8/6/2025 (Estimated)Latest DNLI, BEAM, BBIO, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025BBIOBridgeBio Pharma-$0.50N/AN/AN/AN/AN/A8/7/2025Q2 2025DNLIDenali Therapeutics-$0.73N/AN/AN/AN/AN/A8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share$0.39N/AN/AN/A$68.24 millionN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04N/AN/AN/A$13.29 millionN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A4/29/2025Q1 2025BBIOBridgeBio Pharma-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million4/29/2025Q1 2025VRNAVerona Pharma PLC American Depositary Share-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBIOBridgeBio PharmaN/AN/AN/AN/AN/ABEAMBeam TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBIOBridgeBio PharmaN/A4.574.54BEAMBeam TherapeuticsN/A8.818.81DNLIDenali TherapeuticsN/A9.569.56VRNAVerona Pharma PLC American Depositary Share1.078.868.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBIOBridgeBio Pharma99.85%BEAMBeam Therapeutics99.68%DNLIDenali Therapeutics92.92%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBBIOBridgeBio Pharma18.20%BEAMBeam Therapeutics3.50%DNLIDenali Therapeutics12.50%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBIOBridgeBio Pharma400189.88 million155.32 millionOptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableDNLIDenali Therapeutics430145.28 million127.12 millionOptionableVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableDNLI, BEAM, BBIO, and VRNA HeadlinesRecent News About These CompaniesYeomans Consulting Group Inc. Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)2 hours ago | marketbeat.comBurns Matteson Capital Management LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)4 hours ago | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Sees Unusually-High Trading Volume - Here's What HappenedJuly 16 at 2:18 PM | marketbeat.comWeathering Market Uncertainty? Bet on VIPS, ALKT, FUTU & VRNA NowJuly 16 at 11:11 AM | zacks.comJacobson & Schmitt Advisors LLC Lowers Stock Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 16 at 10:12 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given "Neutral" Rating at HC WainwrightJuly 16 at 3:01 AM | americanbankingnews.comHC Wainwright & Co. Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 11:46 PM | msn.comWhat Makes Verona Pharma PLC American Depositary Share (VRNA) a Strong Momentum Stock: Buy Now?July 15 at 1:01 PM | zacks.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Verona Pharma plc (NASDAQ: VRNA)July 14, 2025 | globenewswire.comPharmaceutical Stocks To Research - July 14thJuly 14, 2025 | marketbeat.comTimesSquare Capital Management LLC Acquires New Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14, 2025 | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14, 2025 | marketbeat.comRice Hall James & Associates LLC Has $52.25 Million Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 14, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at BTIG ResearchJuly 13, 2025 | americanbankingnews.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to Hold at Roth CapitalJuly 13, 2025 | americanbankingnews.comVERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNAJuly 12, 2025 | businesswire.comBTIG Downgrades Verona Pharma plc - Depositary Receipt () (VRNA)July 12, 2025 | msn.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Cut to "Hold" at Wolfe ResearchJuly 12, 2025 | marketbeat.comDiversify Wealth Management LLC Acquires 3,572 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comAlps Advisors Inc. Sells 5,993 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)July 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, BEAM, BBIO, and VRNA Company DescriptionsBridgeBio Pharma NASDAQ:BBIO$47.02 +0.28 (+0.59%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Beam Therapeutics NASDAQ:BEAM$21.17 +0.72 (+3.53%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$14.46 -0.08 (-0.52%) As of 11:07 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$104.88 +0.11 (+0.10%) As of 11:06 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Full Steam Ahead: The Bullish Case for Carnival Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
